Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Clinical improvement of DM1 patients reflected by reversal of disease-induced gene expression in blood

Fig. 1

Distribution of changes in outcome measures per patient. Per outcome measure, changes between baseline and 10 months of CBT were scaled by the root mean square. Additionally, for some outcome measures, a sign adjustment was performed so that an increased score is always associated with improved health status. All outcome measures are shown per patient, where patients were ordered along the y-axis by their change in DM1-Activ-c scores (purple squares). Boxes enclose the 25th to 75th percentiles, divided by a thick line that represents the mean compound response score. The whiskers represent the lowest/highest value no further than 1.5 times the interquartile range. Quality of life (red): Myotonic Dystrophy Health Index, Individualized Neuromuscular Quality of Life Questionnaire, Adult Social Behavioural Questionnaire, Illness Management Questionnaire, Checklist individual strength — Subscale activity. Physical assessments (blue): Six-Minute Walk Test, BORG Scale, accelometery measures. Fatigue scores (black): Fatigue and Daytime Sleepiness Scale, Checklist Individual Strength — Subscale fatigue, Jacobsen Fatigue Catastrophizing Scale. Cognition and other (gray): Trail Making Test, Stroop Color-Word Interference Test, McGill Pain Questionnaire, Beck Depression Inventory — Fast Screen, Social Support — Discrepancies and Negative Interactions, Apathy Evaluation Scale — Clinical version, Self-Efficacy Scale 28

Back to article page